

New Products - Vyvanse

Vyvanse (**lisdexamfetamine dimesilate**) is a pharmacologically inactive prodrug of dexamphetamine. Vyvanse is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). It is contraindicated with advanced arteriosclerosis; symptomatic cardiovascular disease including cardiac arrhythmia, ischaemic heart disease; moderate to severe hypertension; hyperthyroidism; known hypersensitivity to sympathomimetic amines; glaucoma; agitated states such as severe anxiety, tension and agitation; during or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result); phaeochromocytoma; tics, Tourette's syndrome; patients who currently exhibit severe depression, anorexia nervosa, psychotic symptoms or suicidal tendency and in patients with known drug dependence or alcohol abuse. Vyvanse is available as a 30 mg, 50 mg and 70 mg capsule in packs of 30's.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.